The sudden death of Jesse Gelsinger, a patient undergoing experimental treatment
for a rare liver disorder at the University of Pennsylvania, raises scores of
questions about various aspects of gene therapy. Penn officials say Gelsinger's
immune system had a severe inflammatory reaction that caused multiple organs
in his body to fail.